<DOC>
	<DOCNO>NCT02781220</DOCNO>
	<brief_summary>The main purpose study build upon evidence capture Imaging Dementia - Evidence Amyloid Scanning ( IDEAS ; NCT02420756 ) trial include valuable information regard patient-reported outcome physician confidence diagnosis management base Implications Management PET Amyloid Classification Technology ( IMPACT ; NCT number yet assign ) trial design .</brief_summary>
	<brief_title>Implications Management PET Amyloid Classification Technology Imaging Dementia ( IDEAS ) Trial</brief_title>
	<detailed_description>The primary purpose prospective , observational study examine benefit amyloid positron emission tomography compute tomography ( PET/CT ) scan clinical practice participant site enrol IDEAS ( NCT02420756 ) trial . To accomplish , clinician order amyloid PET scan , investigator assess impact [ 18F ] Flutemetamol PET/CT scan 1 ) physician diagnosis management relate care practice drug management , 2 ) patient report outcomes patient evaluate Cognitive Disorders Clinic University Utah meeting Appropriate Use Criteria ( AUC ) clinical amyloid PET/CT scan . A secondary purpose compare semi-quantitative assessment amyloid plaque burden use vendor supply software standard visual assessment amyloid positivity . The primary hypothesis , diagnostically uncertain case , knowledge amyloid status determine amyloid PET/CT scan may alter patient diagnosis management lead significant change patient family report outcomes . A secondary hypothesis vendor supply semi-quantitative assessment amyloid plaque positivity superior standard visual criterion assessment . Objectives AIM 1 : ass change diagnosis management , relate care practice drug management adult patient evaluate cognitive deficit meet Appropriate Use Criteria ( AUC ) AIM 2 : ass change amyloid PET/ CT scan patient-reported outcome involve care partner confidence satisfaction AIM 3 : ass confidence increase use vendor supply semi-quantitative software AIM 4 : ass adherence identify patient management relate care practice drug management</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>65 old ; Medicare beneficiary ; Diagnosis mild cognitive impairment ( MCI ) dementia , accord Diagnostic Statistical Manual IV ( DSMIV ) and/or National Institutes AgingAlzheimer 's Association criterion , verify dementia specialist within 24 month ( American Psychiatric Association . 2000 ; McKhann et al . 2011 ; Albert et al . 2011 ) ; Meets AUC : Cognitive complaint verify objectively confirm cognitive impairment ; The etiologic cause cognitive impairment uncertain comprehensive evaluation dementia specialist , include general medical neurological examination , mental status test include standard measure cognitive impairment , laboratory testing , structural neuroimaging ; Alzheimer 's disease diagnostic consideration ; Knowledge amyloid PET status expect alter diagnosis management . Head MRI and/or CT within 24 month prior enrollment ; Clinical laboratory assessment within 12 month prior enrollment : complete blood count ( CBC ) , standard blood chemistry profile , thyroid stimulate hormone ( TSH ) ; vitamin B12 ; Able tolerate amyloid PET require protocol , perform participate PET facility ; English Spanish speaking ( purpose inform consent ) ; Willing able provide consent . Consent may proxy . Normal cognition subjective complaint verify cognitive testing . Knowledge amyloid status , opinion refer dementia expert , may cause significant psychological harm otherwise negatively impact patient family . Scan order solely base family history dementia , presence apolipoprotein E , lieu genotyping suspect autosomal mutation carrier . Scan order nonmedical purpose ( e.g. , legal , insurance coverage , employment screening ) . Cancer require active therapy ( exclude nonmelanoma skin cancer ) ; Hip/pelvic fracture within 12 month prior enrollment ; Body weight exceeds PET scanner weight limit ; Life expectancy le 24 month base medical comorbidities ; Residence skilled nursing facility .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MCI</keyword>
	<keyword>Dementia</keyword>
	<keyword>amyloid PET</keyword>
	<keyword>physician diagnosis</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>AD</keyword>
	<keyword>PET image</keyword>
	<keyword>Appropriate Use Criteria</keyword>
	<keyword>patient-reported outcome</keyword>
	<keyword>patient adherence</keyword>
</DOC>